The firm recently released two droplet digital PCR-based assays that can characterize edits generated by CRISPR-Cas9 or other genome editing tools.
The UK-based company plans to use the funds to develop an automated, benchtop device for the creation of high-value, genome-edited cell lines.
The two companies plan to combine their respective gene editing and neoantigen discover technologies in order to develop new T cell therapies for cancer patients.
A new BioRxiv preprint says the variants another research team attributed to off-target effects of CRISPR/Cas9 could be natural variation, New Scientist reports.
Investor Peter Thiel has reportedly given $100,000 to the effort to bring back the woolly mammoth, Technology Review reports.
APG Bio will distribute the products and services to life science researchers in China, Hong Kong, and Macau.
In letters, CRISPR companies respond to a Nature Methods report of off-target editing effects, Technology Review reports.
US News & World Reports discusses how gene-editing approaches could be used to treat breast cancer.
CRISPR researchers report that the gene-editing approach might have more off-target effects than thought and urge further refinement of the method.
NPR reports that young students to professionals in other fields are learning how to do CRISPR-based gene editing.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.